Search results
2 companies, 8 research reports and 1 sector report found for "Shire"
Company results
- Shire
Shire is a speciality pharmaceutical company with important franchises in attention deficit hyperact...
- Lancashire Holdings
Lancashire Holdings (LRE) is a global specialty insurance and reinsurance company, domiciled in Berm...
Sector reports
Financials
Cliff edge or knife edge?
Download via: Website
Companies mentioned Amlin, Beazley, Brit Insurance Holdings, Catlin Group, Chaucer Holdings, Hardy Underwriting Bermuda, Hiscox, Lancashire Holdings, Novae Group, Omega Insurance Holdings,
Research results
Sangamo BioSciences
Genome editor
QuickView | Pharmaceutical & Healthcare | 03/02/2012Sangamo shares gained 21% following the announcement of a significant deal with Shire to research novel approaches to treat haemophilia and other mono...
Wolf Minerals
Pre-development works
QuickView | Mining | 06/01/2012We attended a site tour of Wolf Minerals’ world-class Hemerdon tungsten project in Devon, England, on 16 December 2011. Media reports of the UK&...
Lancashire Holdings
Managed risk
Update | Financials | 08/08/2011Lancashire reported a good Q2 result, avoiding material Q2 catastrophe losses (or slippage on Q1 cat loss estimates) despite its focus on low probabil...
Renovo
Juvista mortally scarred
Update | Pharmaceutical & Healthcare | 14/02/2011Renovo’s lead drug, Juvista, has failed its first Phase III trial in scar reductions. Shire will probably return the rights to the drug and further ...
Shire
Win-win situation
QuickView | Pharmaceutical & Healthcare | 04/08/2010Shire proposes to buy GI-focused biotech company Movetis for €428m in cash, effectively €363m net of cash. We estimate that the deal will create â...
Lancashire Holdings
Passed the test
QuickView | Financials | 06/05/2010Lancashire has withstood a testing quarter for large industry losses. Such losses are the nature of LRE’s business and what is pleasing is that it h...
Shire
Tail wind abating
QuickView | Pharmaceutical & Healthcare | 22/02/2010Shire’s FY09 results showed the strength of its young portfolio and the benefits from Genzyme’s contamination problems. Its lead drug Addera...
Renovo
In need of Juvista
Outlook | Pharmaceutical & Healthcare | 08/01/2010Renovo is well capitalised and has traded at or below its cash value for the last 18 months. While this would ostensibly suggest an investment opportu...
